New York, New York - Newsfile Corp.^[1] - June 16, 2021 - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Frequency Therapeutics, Inc. ("Frequency Therapeutics") (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts. To get more information go to:

https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=16815&wire=13^[2]

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.^[3]

Frequency Therapeutics, Inc. NEWS - FREQ NEWS

CASE DETAILS: According to the filed complaint: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Frequency Therapeutics, you have until August 2, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Frequency Therapeutics securities between November 16, 2020 and March 22, 2021, you may be entitled to compensation without payment of any out-of-pocket costs or fees.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=16815&wire=13^[4] or call 212-363-7500 to discuss the case with Joseph E. Levi, Esq.

WHY LEVI & KORSINSKY: Levi & Korsinsky have a proven track record of winning cases worth hundreds of millions of dollars for shareholders over a 20-year period. We represent and fight for shareholders who have been wronged by corporations.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington, D.C. The Firm's Founding Partners, Joseph Levi and Eduard Korsinsky, have been representing shareholders and institutional clients for almost 20 years and have achieved remarkable results for clients in the U.S. and internationally. The firm, with more than 80 employees, is committed to fostering, cultivating, and preserving a culture of diversity, equity and inclusion for employees and those that we represent. Our attorneys have extensive expertise representing investors in securities litigation with a track record of recovering hundreds of millions of dollars in cases. Levi & Korsinsky was ranked in Institutional Shareholder Services' ("ISS") SCAS Top 50 Report for 7 years in a row as a top securities litigation firm in the United States. The SCAS Top 50 Report identifies the top plaintiffs' securities law firms in the country, and year after year, ISS has recognized Levi & Korsinsky as a leading firm in the area of securities class action litigation.

CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.Ed Korsinsky, Esq.55 Broadway, 10th FloorNew York, NY 10006jlevi@levikorsinsky.comTel: (212) 363-7500Fax: (212) 363-7171www.zlk.com^[5][6]

References

1. ^{^} Newsfile Corp. (www.newsfilecorp.com)
2. ^{^} https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=16815&wire=13 (www.zlk.com)
3. ^{^} jlevi@levikorsinsky.com (www.media-outreach.com)
4. ^{^} https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=16815&wire=13 (www.zlk.com)
5. ^{^} jlevi@levikorsinsky.com (www.media-outreach.com)
6. ^{^} www.zlk.com (www.zlk.com)